pancreatic cancer - PMC

Result Filters

You searched 8+ million full text articles

Try this search in 34+ million citations and abstracts

PMC Full-Text Search Results

Items: 1 to 20 of 437884

<< First< Prev

Page of 21895

Next >Last >>

Select item 104240881.

Screening for pancreatic cancer has the potential to save lives, but is it practical?

Benjamin L. Mazer, Jae W. Lee, Nicholas J. Roberts, Linda C. Chu, Anne Marie Lennon, Alison P. Klein, James R. Eshleman, Elliot K. Fishman, Marcia Irene Canto, Michael G. Goggins, Ralph H. Hruban

Expert Rev Gastroenterol Hepatol. Author manuscript; available in PMC 2024 Jul 3.

Published in final edited form as: Expert Rev Gastroenterol Hepatol. 2023 Jan-Jun; 17(6): 555–574. Published online 2023 Jul 3. doi: 10.1080/17474124.2023.2217354

PMCID:: PMC10424088

Abstract Article PDF–1.7M

Select item 80415692.

Artificial Intelligence and Early Detection of Pancreatic Cancer: 2020 Summative Review

Barbara Kenner, Suresh T. Chari, David Kelsen, David S. Klimstra, Stephen J. Pandol, Michael Rosenthal, Anil K. Rustgi, James A. Taylor, Adam Yala, Noura Abul-Husn, Dana K. Andersen, David Bernstein, Søren Brunak, Marcia Irene Canto, Yonina C. Eldar, Elliot K. Fishman, Julie Fleshman, Vay Liang W. Go, Jane M. Holt, Bruce Field, Ann Goldberg, William Hoos, Christine Iacobuzio-Donahue, Debiao Li, Graham Lidgard, Anirban Maitra, Lynn M. Matrisian, Sung Poblete, Laura Rothschild, Chris Sander, Lawrence H. Schwartz, Uri Shalit, Sudhir Srivastava, Brian Wolpin

Pancreas. 2021 Mar; 50(3): 251–279. Published online 2021 Apr 8. doi: 10.1097/MPA.0000000000001762

PMCID:: PMC8041569

Abstract Article PDF–974K

Select item 102433023.

Pancreatic Cancer: Changing Epidemiology and New Approaches to Risk Assessment, Early Detection, and Prevention

Elena M. Stoffel, Randall E. Brand, Michael Goggins

Gastroenterology. Author manuscript; available in PMC 2023 Jun 6.

Published in final edited form as: Gastroenterology. 2023 Apr; 164(5): 752–765. Published online 2023 Feb 18. doi: 10.1053/j.gastro.2023.02.012

PMCID:: PMC10243302

Abstract Article PDF–639K

Select item 103264184.

Novel strategy for oncogenic alteration-induced lipid metabolism reprogramming in pancreatic cancer: The function of lipid metabolism reprogramming in pancreatic cancer

Duancheng Guo, Longyun Ye, Weiding Wu, Xianjun Yu, Kaizhou Jin

Acta Biochim Biophys Sin (Shanghai) 2023 Jun; 55(6): 923–937. Published online 2023 Apr 6. doi: 10.3724/abbs.2023045

PMCID:: PMC10326418

Abstract Article PDF–1.1M

Select item 105989805.

Antibody drug conjugates: hitting the mark in pancreatic cancer?

Nicole L. Wittwer, Michael P. Brown, Vasilios Liapis, Alexander H. Staudacher

J Exp Clin Cancer Res. 2023; 42: 280. Published online 2023 Oct 25. doi: 10.1186/s13046-023-02868-x

PMCID:: PMC10598980

Abstract Article PDF–1.5M

Select item 113097466.

The role of biomarkers in the early detection of pancreatic cancer

Michael Goggins

Fam Cancer. Author manuscript; available in PMC 2024 Aug 8.

Published in final edited form as: Fam Cancer. 2024 Aug; 23(3): 309–322. Published online 2024 Apr 25. doi: 10.1007/s10689-024-00381-4

PMCID:: PMC11309746

Abstract Article PDF–374K

Select item 101828307.

Pancreatic Cancer: Advances and Challenges

Christopher J. Halbrook, Costas A. Lyssiotis, Marina Pasca di Magliano, Anirban Maitra

Cell. Author manuscript; available in PMC 2024 Apr 13.

Published in final edited form as: Cell. 2023 Apr 13; 186(8): 1729–1754. doi: 10.1016/j.cell.2023.02.014

PMCID:: PMC10182830

Abstract Article PDF–2.1M

Select item 63650138.

New developments in the molecular mechanisms of pancreatic tumorigenesis

Matthäus Felsenstein, Ralph H. Hruban, Laura D. Wood

Adv Anat Pathol. Author manuscript; available in PMC 2019 Mar 1.

Published in final edited form as: Adv Anat Pathol. 2018 Mar; 25(2): 131–142. doi: 10.1097/PAP.0000000000000172

PMCID:: PMC6365013

Abstract Article PDF–944K

Select item 82553199.

The molecular biology of pancreatic adenocarcinoma: translational challenges and clinical perspectives

Shun Wang, Yan Zheng, Feng Yang, Le Zhu, Xiao-Qiang Zhu, Zhe-Fang Wang, Xiao-Lin Wu, Cheng-Hui Zhou, Jia-Yan Yan, Bei-Yuan Hu, Bo Kong, De-Liang Fu, Christiane Bruns, Yue Zhao, Lun-Xiu Qin, Qiong-Zhu Dong

Signal Transduct Target Ther. 2021; 6: 249. Published online 2021 Jul 5. doi: 10.1038/s41392-021-00659-4

PMCID:: PMC8255319

Abstract Article PDF–3.2M

Select item 837558510.

The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go

Elizabeth D. Thompson, Nicholas J. Roberts, Laura D. Wood, James R. Eshleman, Michael G. Goggins, Scott E. Kern, Alison P. Klein, Ralph H. Hruban

Mod Pathol. Author manuscript; available in PMC 2021 Dec 1.

Published in final edited form as: Mod Pathol. 2020 Dec; 33(12): 2544–2563. Published online 2020 Jul 23. doi: 10.1038/s41379-020-0629-6

PMCID:: PMC8375585

Abstract Article PDF–1.5M

Select item 772200211.

Multidisciplinary standards of care and recent progress in pancreatic ductal adenocarcinoma

Aaron J. Grossberg, Linda C. Chu, Christopher R. Deig, Eliot K. Fishman, William L. Hwang, Anirban Maitra, Daniel L. Marks, Arnav Mehta, Nima Nabavizadeh, Diane M. Simeone, Colin D. Weekes, Charles R. Thomas, Jr.

CA Cancer J Clin. Author manuscript; available in PMC 2021 Sep 1.

Published in final edited form as: CA Cancer J Clin. 2020 Sep; 70(5): 375–403. Published online 2020 Jul 19. doi: 10.3322/caac.21626

PMCID:: PMC7722002

Abstract Article PDF–1.6M

Select item 831502212.

Microorganisms in chemotherapy for pancreatic cancer: An overview of current research and future directions

Si-Yuan Lu, Jie Hua, Jin Xu, Miao-Yan Wei, Chen Liang, Qing-Cai Meng, Jiang Liu, Bo Zhang, Wei Wang, Xian-Jun Yu, Si Shi

Int J Biol Sci. 2021; 17(10): 2666–2682. Published online 2021 Jun 26. doi: 10.7150/ijbs.59117

PMCID:: PMC8315022

Abstract Article PDF–2.2M

Select item 951644013.

Pancreatic Cancer: Pathogenesis, Screening, Diagnosis, and Treatment

Laura D. Wood, Marcia Irene Canto, Elizabeth M. Jaffee, Diane M. Simeone

Gastroenterology. Author manuscript; available in PMC 2023 Aug 1.

Published in final edited form as: Gastroenterology. 2022 Aug; 163(2): 386–402.e1. Published online 2022 Apr 7. doi: 10.1053/j.gastro.2022.03.056

PMCID:: PMC9516440

Abstract Article PDF–1.7M

Select item 856397314.

Mutations in key driver genes of pancreatic cancer: molecularly targeted therapies and other clinical implications

Hai-feng Hu, Zeng Ye, Yi Qin, Xiao-wu Xu, Xian-jun Yu, Qi-feng Zhuo, Shun-rong Ji

Acta Pharmacol Sin. 2021 Nov; 42(11): 1725–1741. Published online 2021 Feb 11. doi: 10.1038/s41401-020-00584-2

PMCID:: PMC8563973

Abstract Article PDF–1.6M

Select item 587395715.

Inherited Pancreatic Cancer

Fei Chen, Nicholas J. Roberts, Alison P. Klein

Chin Clin Oncol. Author manuscript; available in PMC 2018 Dec 1.

Published in final edited form as: Chin Clin Oncol. 2017 Dec; 6(6): 58. doi: 10.21037/cco.2017.12.04

PMCID:: PMC5873957

Abstract Article PDF–382K

Select item 883570016.

Molecular Features and Clinical Management of Hereditary Pancreatic Cancer Syndromes and Familial Pancreatic Cancer

Akiyoshi Kasuga, Takeshi Okamoto, Shohei Udagawa, Chinatsu Mori, Takafumi Mie, Takaaki Furukawa, Yuto Yamada, Tsuyoshi Takeda, Masato Matsuyama, Takashi Sasaki, Masato Ozaka, Arisa Ueki, Naoki Sasahira

Int J Mol Sci. 2022 Feb; 23(3): 1205. Published online 2022 Jan 21. doi: 10.3390/ijms23031205

PMCID:: PMC8835700

Abstract Article PDF–361K

Select item 1047060517.

Epithelial and stromal co-evolution and complicity in pancreatic cancer

Sunil R. Hingorani

Nat Rev Cancer. Author manuscript; available in PMC 2023 Aug 31.

Published in final edited form as: Nat Rev Cancer. 2023 Feb; 23(2): 57–77. Published online 2022 Nov 29. doi: 10.1038/s41568-022-00530-w

PMCID:: PMC10470605

Abstract Article PDF–1.4M

Select item 926584718.

Pancreatic cancer epidemiology: understanding the role of lifestyle and inherited risk factors

Alison P. Klein

Nat Rev Gastroenterol Hepatol. Author manuscript; available in PMC 2022 Jul 8.

Published in final edited form as: Nat Rev Gastroenterol Hepatol. 2021 Jul; 18(7): 493–502. Published online 2021 May 17. doi: 10.1038/s41575-021-00457-x

PMCID:: PMC9265847

Abstract Article PDF–632K

Select item 1133298719.

Systemic treatments in pancreatic cancer: Taiwan pancreas society recommendation

Yung-Yeh Su, Nai-Jung Chiang, Tai-Jan Chiu, Chien-Jui Huang, Shao-Jung Hsu, Hsin-Chen Lin, Shih-Hung Yang, Youngsen Yang, Wen-Chi Chou, Yen-Yang Chen, Li-Yuan Bai, Chung-Pin Li, Jen-Shi Chen

Biomed J. 2024 Jun; 47(3): 100696. Published online 2023 Dec 31. doi: 10.1016/j.bj.2023.100696

PMCID:: PMC11332987

Abstract Article PDF–585K

Select item 1032213320.

Management of Patients With Pancreatic Cancer Using the “Right Track” Model

Allison Rosenzweig, Jordan Berlin, Suresh Chari, Hedy Kindler, Lynn Matrisian, Allison Mayoral, Jeannine Mills, Nicholas Nissen, Vincent Picozzi, Fatima Zelada-Arenas, Jason Fleming

Oncologist. 2023 Jul; 28(7): 584–595. Published online 2023 Apr 12. doi: 10.1093/oncolo/oyad080

PMCID:: PMC10322133

Abstract Article PDF–1.7M

<< First< Prev

Page of 21895

Next >Last >>

Supplemental Content

Filter your results:

Manage Filters

PMC Images search for pancreatic cancer

Fig. 1The overview of the tsRNAs expressions in three primary pancreatic cancer tissues and liver metastases tissues of pancreatic cancer.

A The principal component analysis (PCA) of tsRNAs expressions in primary and metastatic pancreatic cancer samples. M: metastatic pancreatic cancer. P: primary pancreatic cancer. B Correlation heatmap analysis of tsRNAs expressions in primary and metastatic pancreatic cancer samples. M: metastatic pancreatic cancer. P: primary pancreatic cancer. C Schematic diagram of tsRNA classification. D The distribution of tsRNAs subtype numbers in primary (right panel) and metastatic samples (left panel). E Length of different tsRNA classifications and number in primary and metastatic samples. F The numbers of subtype tsRNAs against tRNA isodecoders in primary and metastatic pancreatic cancer sample. M: metastatic pancreatic cancer. P: primary pancreatic cancer. F The distribution of tsRNAs subtype numbers in primary and metastatic samples. G Venn diagram based on number of commonly expressed and specifically expressed tsRNAs in primary and metastatic samples. The scatter plot (H) between and heatmap (I) of tsRNAs in primary and metastatic pancreatic cancer samples. M: metastatic pancreatic cancer; P: primary pancreatic cancer.

tiRNA-Val-CAC-2 interacts with FUBP1 to promote pancreatic cancer metastasis by activating c‑MYC transcription

Oncogene. 2024;43(17):1274-1287.
Fig. 3

Expression, survival, interacting and correlation analyses of the RIPKs family members. A RIPK1 expression between pancreatic cancer and normal tissues and its relevance to the survival of pancreatic cancer patients. B RIPK3 expression between pancreatic cancer and normal tissues and its relevance to the survival of pancreatic cancer patients. C RIPK4 expression between pancreatic cancer and normal tissues and its relevance to the survival of pancreatic cancer patients. D RIPK5 (DSTYK) expression between pancreatic cancer and normal tissues and its relevance to the survival of pancreatic cancer patients. E RIPK6 (LRRK1) expression between pancreatic cancer and normal tissues and its relevance to the survival of pancreatic cancer patients. F RIPK7 (LRRK2) expression between pancreatic cancer and normal tissues and its relevance to the survival of pancreatic cancer patients. G The interactions and correlations among seven members of RIPKs family. **p < 0.01, ***p < 0.001

Paired protein kinases PRKCI-RIPK2 promote pancreatic cancer growth and metastasis via enhancing NF-κB/JNK/ERK phosphorylation

Mol Med. 2023;29:47.
Figure 7

Prognostic values of miRNAs in pancreatic cancer. (A) Prognostic value of has-miR-132 in pancreatic cancer. (B) Prognostic value of has-miR-133a in pancreatic cancer. (C) Prognostic value of has-miR-29b in pancreatic cancer. (D) Prognostic value of has-miR-491 in pancreatic cancer. (E) Prognostic value of has-miR-192 in pancreatic cancer. (F) Prognostic value of has-miR-29c in pancreatic cancer. (G) Prognostic value of has-miR-9 in pancreatic cancer. (H) Prognostic value of has-miR-140 in pancreatic cancer.

A novel mRNA-miRNA-lncRNA competing endogenous RNA triple sub-network associated with prognosis of pancreatic cancer

Aging (Albany NY). 2019 May 15;11(9):2610-2627.
Figure 8

Identification of upstream potential miRNAs of APOL1, COL12A1 and MMP14 by combination of miRNA prediction, survival analysis and correlation analysis. (A) The miRNA- APOL1 network established by Cytoscape. (B) The miRNA- COL12A1 network established by Cytoscape. (C) The miRNA-MMP14 network established by Cytoscape. (D) Prognostic value of has- miR-26b-5p in pancreatic cancer. (E) Prognostic value of has- miR-375 in pancreatic cancer. (F) Prognostic value of has-miR-9-5p in pancreatic cancer. (G) Prognostic value of has- miR-455-3p in pancreatic cancer. (H) Prognostic value of has- miR-545-3p in pancreatic cancer. (I) Prognostic value of has-miR-551b-5p in pancreatic cancer. (J) Prognostic value of has- miR-335-5p in pancreatic cancer. (K) Prognostic value of has- miR-133a-3p in pancreatic cancer. (L) The expression correlation of has- miR-26b-5p and COL12A1 in pancreatic cancer. (M) The expression correlation of has-miR-9-5p and COL12A1 in pancreatic cancer. (N) The expression correlation of has-miR-551b-5p and COL12A1 in pancreatic cancer. (O) The expression correlation of has- miR-545-3p and COL12A1 in pancreatic cancer. (P) The expression correlation of has- miR-133a-3p and MMP14 in pancreatic cancer.

Identification of a new pseudogenes/lncRNAs-hsa-miR-26b-5p-COL12A1 competing endogenous RNA network associated with prognosis of pancreatic cancer using bioinformatics analysis

Aging (Albany NY). 2020 Oct 15;12(19):19107-19128.